Confirmation that p16INK4a is involved in CDK6’s tumor-suppressing role was obtained from experiments with p16INK4a/p19ARF-deficient animals and the CDK6R31C mutant unable to bind INK proteins. Here, CDKN2A is linked to neoplasm.